Apixaban - CAS# 503612-47-3 size:2mg solid Acquired mutations in BCL2 family

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Coinhibition of the deubiquitinating enzymes

For Sight: The Future of Eye and Vision Research--part 2

Epub 2019 May 14

Novel phosphoinositide 3-kinase/mTOR dual inhibitor

Apixaban - CAS# 503612-47-3 size:2mg solid Acquired mutations in BCL2 familyApixaban, CAS No. 503612 47 3, also known as BMS 56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement